Evidence map›Paper›PMID 40686853›Full record

ArticleMolecular therapy. Nucleic acids2025

RNA activation of

Olivia Kovecses, Bahram Sharif-Askari, Cristobal Gonzalez-Losada, Vikash Reebye, Bríd M Ryan, Nathan W Luedtke, François E Mercier, Maureen McKeague

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Olivia KovecsesDepartment of Pharmacology & Therapeutics, McGill University, Montreal, Québec H3G 1Y6, Canada.
Bahram Sharif-AskariLady Davis Institute for Medical Research & Cancer Segal Center, Jewish General Hospital, Montreal, Québec H3T 1E1, Canada.
Cristobal Gonzalez-LosadaDivision of Clinical and Translational Research, Department of Medicine, McGill University, Montreal, Québec H4A 3J1, Canada.
Vikash ReebyeMiNA Therapeutics, Translation & Innovation Hub, London W12 0BZ, UK.
Bríd M RyanMiNA Therapeutics, Translation & Innovation Hub, London W12 0BZ, UK.
Nathan W LuedtkeDepartment of Pharmacology & Therapeutics, McGill University, Montreal, Québec H3G 1Y6, Canada.
François E MercierLady Davis Institute for Medical Research & Cancer Segal Center, Jewish General Hospital, Montreal, Québec H3T 1E1, Canada.
Maureen McKeagueDepartment of Pharmacology & Therapeutics, McGill University, Montreal, Québec H3G 1Y6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a highly aggressive blood cancer marked by impaired differentiation and uncontrolled proliferation of myeloid cells. This phenotype is often driven by dysregulated expression of the transcription factor C/EBPα (encoded by

Indexed as

acute myeloid leukemiaCEBPAdrug deliveryFLT3-ITDMT: Oligonucleotides: Therapies and Applicationsmyeloid differentiationnucleic acid therapeuticssmall activating RNAtranscription factorstyrosine kinase inhibitors

Identifiers

PMID40686853
PMCPMC12271619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.